Navigation Links
BioMS Medical Announces Second Quarter 2008 Results
Date:8/12/2008

nt of SPMS. Enrollment for the randomized, double-blind study was initiated in June, 2007 and on July 31, 2008, BioMS completed full recruitment of approximately 510 patients at 68 sites across the U.S. To date, the DSMB has conducted two reviews of the data from this trial and has recommended it continue.

(x) MINDSET-01: A phase II clinical trial evaluating MBP8298 (dirucotide) for the treatment of relapsing-remitting MS (RRMS). The randomized, double-blind study has completed recruitment with 218 patients enrolled at 24 trial sites in six countries across Europe. The DSMB has completed five safety reviews to date and recommended that the trial continue as per the protocol. Completion of the trial is expected at the end of 2008 with results anticipated in the first half of 2009.

Licensing and Development Agreement

On December 17, 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 (dirucotide). Under the terms of the agreement, Lilly and BioMS will collaborate on the development of MBP8298 (dirucotide) and will also share in certain development costs with Lilly being responsible for future research and development, manufacturing and marketing activities. The transaction closed on January 25, 2008 with the receipt of an upfront payment of US$87 million. BioMS has the potential to receive additional development and sales milestones of up to US $410 million and escalating royalties on sales commensurate with the current stage of development of the product if MBP8298 (dirucotide) is commercialized.

Financial Results

The consolidated net loss for the three months ended June 30, 2008 was $0.4 million or ($0.00) per share compared to a consolidated net loss of $11.8 million or ($0.14) per share for the three months ended June 30, 2007. The consolidated net loss for the six months ended June 30, 2008 was $7.1 million or ($0.08) per share compared to a consolid
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... September 01, 2014 The global ... million by 2019 from $1,070.7 million in 2014, ... to 2019. The global oligonucleotide synthesis market is ... applications, end users, and geography. The synthesized oligonucleotides ... rate in the oligonucleotide synthesis market during the ...
(Date:8/31/2014)... 2014 Market Research Report ... and in-depth research report on the Polyacrylamide ... including Polyacrylamide definition, classification, application, and industry ... This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic ...
(Date:8/29/2014)... electrons, but one of the most promising technologies for ... on light (photons) instead of electrons. First, it is ... single photons and control their direction. Researchers around the ... this control, but now scientists at the Niels Bohr ... photons emitted one at a time and in a ...
(Date:8/29/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the six months ended June 30, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... , Announced top-line results related to the eight ... enrolled in the Phase 2 iDEAL Study evaluating ...
Breaking Biology Technology:9.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4
... /PRNewswire/ -- The Nano Science and Technology Institute ... will take place May 3-7, 2009 at the George R. ... 12th year, the largest and most prominent Nanotechnology event is ... Micro and Bio technology executives, who will gather to promote ...
... CLINTON, N.J., Jan. 8 Ikaria Holdings, Inc. today ... present at the 27th Annual JPMorgan Healthcare Conference on ... The conference will be held January 12-15 at The ... Holdings, Inc. , Ikaria Holdings, Inc. is a ...
... /PRNewswire/ - Aegera Therapeutics Inc. announced today the ... Phase 2 study of AEG35156, their targeted antisense ... , The study, entitled "A Phase 2, Multicenter, ... Apoptosis (XIAP) Antisense AEG35156 Given In Combination With ...
Cached Biology Technology:NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 2NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 3NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 4Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference 2Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer 2
(Date:9/1/2014)... after birth, every child in the U.S. undergoes a ... conditions, including sickle cell disease. Thousands of children born ... many suffer and die from the disease each year. ... to at least some of those deaths. , ... in the lab of George Whitesides, the Woodford L. ...
(Date:9/1/2014)... basic building block of DNAcould initiate fragile X syndrome, the most ... The Journal of Cell Biology . , ... on the X chromosome called fragile X mental retardation 1 ... men carry a so-called premutation, in which a series of DNA ... slightly longer than normal. These repeats are prone to even further ...
(Date:9/1/2014)... to a life without light. They emit echolocation sounds and ... to obstacles or prey. In their brains, they have a ... by researchers at Technische Universitt Mnchen (TUM) has shown for ... factors. , Closer objects appear larger ... object, the number of activated neurons in its brain increases. ...
Breaking Biology News(10 mins):Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2
... June 1, 2010 -- The National Oceanic and Atmospheric ... of Miami (UM) to continue to lead its partnership ... (CIMAS). NOAA and UM scientists have worked ... of climate, hurricanes, and marine ecosystems along the southeastern ...
... Since the 1990s, a green fluorescent protein known simply as ... Northwest jellyfish, GFP allows scientists to visualize proteins inside of ... Two years ago, biologists who discovered and developed the protein ... work. However, using GFP as a fluorescent probe has ...
... viable due to aberrant chromosome distribution if they had ... German Cancer Research Center have investigated which genes are ... revealed that cancer cells rely on the tension ... Thus, proteins which maintain this tension are promising targets ...
Cached Biology News:NOAA selects University of Miami to lead major southeastern US cooperative institute 2NOAA selects University of Miami to lead major southeastern US cooperative institute 3MIT chemists design new way to fluorescently label proteins 2No relaxing for cancer cells 2
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... Major Science Smart Minis 150V power supply ... mini power supplies designed to meet most ... to use unit. The Minis 150V power ... The Minis Power Supply is designed for ...
Biology Products: